CA3030792C - Procédé et système de pharmacogénomique microbienne - Google Patents

Procédé et système de pharmacogénomique microbienne

Info

Publication number
CA3030792C
CA3030792C CA3030792A CA3030792A CA3030792C CA 3030792 C CA3030792 C CA 3030792C CA 3030792 A CA3030792 A CA 3030792A CA 3030792 A CA3030792 A CA 3030792A CA 3030792 C CA3030792 C CA 3030792C
Authority
CA
Canada
Prior art keywords
microbiome
antibiotics
features
pharmacogenomics
user
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3030792A
Other languages
English (en)
Other versions
CA3030792A1 (fr
Inventor
Zachary Apte
Jessica Richman
Daniel Almonacid
Inti Pedroso
Juan Ugalde
Rodrigo Ortiz
Original Assignee
Psomagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/606,743 external-priority patent/US10803991B2/en
Application filed by Psomagen Inc filed Critical Psomagen Inc
Publication of CA3030792A1 publication Critical patent/CA3030792A1/fr
Application granted granted Critical
Publication of CA3030792C publication Critical patent/CA3030792C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/74—Details of notification to user or communication with user or patient; User input means
    • A61B5/746—Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/74—Details of notification to user or communication with user or patient; User input means
    • A61B5/7465—Arrangements for interactive communication between patient and care services, e.g. by using a telephone network
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/13—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Data Mining & Analysis (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Nursing (AREA)
  • Physiology (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Databases & Information Systems (AREA)

Abstract

Des modes de réalisation d’un procédé et d’un système pour la pharmacogénomique microbienne peuvent comprendre : un système de manipulation d’échantillons opérationnel pour collecter des conteneurs comprenant des échantillons biologiques provenant d’un ensemble d’utilisateurs, le système de manipulation comprenant un système de séquençage opérationnel pour déterminer des séquences de micro-organismes à partir des échantillons biologiques ; un système de caractérisation de microbiome opérationnel pour : déterminer des données de pharmacogénomique de microbiome sur la base des séquences de micro-organisme, collecter des données supplémentaires associées à l’état associé aux antibiotiques pour l’ensemble d’utilisateurs, et transformer les données et caractéristiques supplémentaires extraites des données de pharmacogénomique du microbiome dans un modèle de caractérisation associé à l’état associé aux antibiotiques ; et un système de traitement opérationnel pour favoriser un traitement de l’utilisateur pour l’état associé aux antibiotiques sur la base de la caractérisation de matériau biologique d’utilisateur avec le modèle de caractérisation en relation avec l’état associé aux antibiotiques.
CA3030792A 2016-07-13 2017-07-13 Procédé et système de pharmacogénomique microbienne Active CA3030792C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662361943P 2016-07-13 2016-07-13
US62/361,943 2016-07-13
US15/606,743 2017-05-26
US15/606,743 US10803991B2 (en) 2014-10-21 2017-05-26 Method and system for microbiome-derived diagnostics and therapeutics
PCT/US2017/042015 WO2018013865A1 (fr) 2016-07-13 2017-07-13 Procédé et système de pharmacogénomique microbienne

Publications (2)

Publication Number Publication Date
CA3030792A1 CA3030792A1 (fr) 2018-01-18
CA3030792C true CA3030792C (fr) 2025-06-10

Family

ID=60953350

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3030792A Active CA3030792C (fr) 2016-07-13 2017-07-13 Procédé et système de pharmacogénomique microbienne

Country Status (12)

Country Link
EP (1) EP3484348A4 (fr)
JP (2) JP2019521706A (fr)
KR (1) KR102397683B1 (fr)
CN (1) CN109475305B (fr)
AU (1) AU2017295861A1 (fr)
BR (1) BR112019000709A8 (fr)
CA (1) CA3030792C (fr)
CO (1) CO2019001319A2 (fr)
EA (1) EA201990294A1 (fr)
SG (1) SG11201900253TA (fr)
WO (1) WO2018013865A1 (fr)
ZA (1) ZA201900473B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112004943A (zh) * 2017-12-04 2020-11-27 赛百乐微生物有限公司 用于鉴定并调节微生物组生化途径以改变表型的方法和组合物
EP3766073A4 (fr) * 2018-03-16 2021-12-15 Psomagen, Inc. Procédé et système de caractérisation d'états associés au métabolisme, comprenant des diagnostics et des thérapies, sur la base d'une approche bioinformatique
JP7455757B2 (ja) 2018-04-13 2024-03-26 フリーノーム・ホールディングス・インコーポレイテッド 生体試料の多検体アッセイのための機械学習実装
CA3101541A1 (fr) * 2018-06-07 2019-12-12 4D Pharma Plc Procede de stratification de patients atteints du sii
KR102346398B1 (ko) 2020-09-01 2022-01-03 주식회사 에이아이바이오틱스 장내 미생물을 분석하여 평가 하는 시스템 및 평가 방법
US20240127925A1 (en) * 2021-02-03 2024-04-18 Tata Consultancy Services Limited Method and system for designing personalized therapeutics and diet based on functions of microbiome
US20220367050A1 (en) * 2021-05-12 2022-11-17 Zoe Limited Predicting gut microbiome diversity
KR102884203B1 (ko) 2022-12-22 2025-11-11 주식회사 오디엔 약물치료 관리 시스템 및 그 동작방법
WO2024226805A2 (fr) * 2023-04-25 2024-10-31 Rutgers, The State University Of New Jersey Procédés pour prédire une réponse à une thérapie pour un trouble par le biais de guildes de microbiome central
CN119106344B (zh) * 2024-10-28 2025-07-22 南京大学 一种基于机器学习的微生物群落最优微生境识别方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100551104B1 (ko) * 1994-12-09 2006-02-09 임페리얼 컬리지 이노베이션스 리미티드 유전자의 동정
JP5557415B2 (ja) * 2003-06-02 2014-07-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物
US7955837B2 (en) * 2005-10-29 2011-06-07 Bayer Technology Services Gmbh Process for determining one or more analytes in samples of biological origin having complex composition, and use thereof
CN102027129B (zh) * 2008-02-28 2014-03-12 俄亥俄州立大学研究基金会 用于前列腺相关病症的诊断、预后和治疗的基于微rna的方法和组合物
KR20110101143A (ko) * 2008-11-04 2011-09-15 블러드 셀 스토리지 인코퍼레이티드 굴곡 유리 표면 상에서의 핵산 추출
WO2011093674A2 (fr) * 2010-01-29 2011-08-04 (주)유바이오메드 Micro-aiguille et dispositif à micro-aiguille
LT2547361T (lt) * 2010-03-17 2020-12-28 Socpra - Sciences Et Génie, S.E.C. Staphylococcus aureus bakterinės vakcinos komponentai ir jų naudojimas
CN101833613A (zh) * 2010-06-04 2010-09-15 中国科学院青岛生物能源与过程研究所 一种口腔微生物群落数据库及其应用
US20130121968A1 (en) * 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles
US9719144B2 (en) * 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
US20140143188A1 (en) * 2012-11-16 2014-05-22 Genformatic, Llc Method of machine learning, employing bayesian latent class inference: combining multiple genomic feature detection algorithms to produce an integrated genomic feature set with specificity, sensitivity and accuracy
JP2016509003A (ja) * 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 組成物および方法
US9466024B2 (en) * 2013-03-15 2016-10-11 Northrop Grumman Systems Corporation Learning health systems and methods
US20160045158A1 (en) * 2013-03-15 2016-02-18 Prometheon Pharma, Llc Devices, systems, and methods for transdermal delivery of compounds
US20150019189A1 (en) * 2013-07-01 2015-01-15 Counterpoint Health Solutions, Inc. Systems biology approach to therapy
JP6637885B2 (ja) * 2013-07-21 2020-01-29 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオームの特性解明、モニタリング、および処置のための方法およびシステム
WO2015066625A1 (fr) * 2013-11-01 2015-05-07 Washington University Méthodes pour établir et restaurer la fonction normale du microbiote intestinal chez un sujet en ayant besoin
AU2015209718B2 (en) * 2014-01-25 2021-03-25 Macrogen Inc. Method and system for microbiome analysis
WO2016057679A1 (fr) * 2014-10-09 2016-04-14 LuminaCare Solutions Inc. Plateforme de dosage personnalisé d'antibiotiques
WO2016065075A1 (fr) * 2014-10-21 2016-04-28 uBiome, Inc. Procédé et système de diagnostic et de thérapie fondés sur le microbiome
AU2015358251A1 (en) * 2014-12-05 2017-06-29 University Of Saskatchewan Methods and reagents for detecting neisseria gonorrhoeae and its antimicrobial resistance determinants
CN105648060B (zh) * 2016-01-29 2020-01-31 江汉大学 一种非诊断目的的人体病原微生物耐药性基因的检测方法

Also Published As

Publication number Publication date
ZA201900473B (en) 2019-09-25
JP2019521706A (ja) 2019-08-08
CO2019001319A2 (es) 2019-02-19
CN109475305B (zh) 2022-01-25
SG11201900253TA (en) 2019-02-27
BR112019000709A2 (pt) 2019-05-14
KR20190033561A (ko) 2019-03-29
BR112019000709A8 (pt) 2023-03-21
KR102397683B1 (ko) 2022-05-13
AU2017295861A1 (en) 2019-01-24
EA201990294A1 (ru) 2019-08-30
EP3484348A1 (fr) 2019-05-22
JP2022079646A (ja) 2022-05-26
EP3484348A4 (fr) 2021-11-24
CA3030792A1 (fr) 2018-01-18
CN109475305A (zh) 2019-03-15
WO2018013865A1 (fr) 2018-01-18

Similar Documents

Publication Publication Date Title
US10789334B2 (en) Method and system for microbial pharmacogenomics
CA3030792C (fr) Procédé et système de pharmacogénomique microbienne
CN107849599B (zh) 用于诊断测试的方法和系统
US11001900B2 (en) Method and system for characterization for female reproductive system-related conditions associated with microorganisms
US10388407B2 (en) Method and system for characterizing a headache-related condition
WO2019046347A9 (fr) Procédé et système de caractérisation de conditions liées à un système reproducteur féminin associées à des micro-organismes
AU2022202660A1 (en) Method and system for characterization for appendix-related conditions associated with microorganisms
JP7114091B2 (ja) パネル特徴付けのための方法およびシステム
US20180342322A1 (en) Method and system for characterization for appendix-related conditions associated with microorganisms
AU2017229488A1 (en) Method and system for characterizing mouth-associated conditions
CN108350019A (zh) 用于细菌性阴道病的源自微生物群系的诊断及治疗方法和系统
US11783914B2 (en) Method and system for panel characterizations
AU2018327227A1 (en) Nasal-related characterization associated with the nose microbiome
EP3776285A1 (fr) Procédé et système destinés à la caractérisation d'états pathologiques apparentés à un microorganisme
US20190019575A1 (en) Nasal-related characterization associated with the nose microbiome
US20190211378A1 (en) Method and system for microbiome-derived diagnostics and therapeutics for cerebro-craniofacial health
EP3687375A1 (fr) Procédé et système pour caractériser une affection liée à une céphalée
CA3036994C (fr) Methode et systeme de caracterisations de panel

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211129

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20240709

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20250430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250430

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20250603

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20250610

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250620

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250623